Literature DB >> 23027801

Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: an analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial.

Harriette G C Van Spall1, Lars Wallentin, Salim Yusuf, John W Eikelboom, Robby Nieuwlaat, Sean Yang, Conrad Kabali, Paul A Reilly, Michael D Ezekowitz, Stuart J Connolly.   

Abstract

BACKGROUND: The outcome of atrial fibrillation patients on warfarin partially depends on maintaining adequate time in therapeutic International Normalized Ratio range (TTR). Large differences in TTR have been reported between centers and countries. The association between warfarin dosing practice, TTR, and clinical outcomes was evaluated in Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial patients receiving warfarin. METHODS AND
RESULTS: RE-LY provided an algorithm for warfarin dosing, recommending no change for in-range, and 10% to 15% weekly dose changes for out-of-range International Normalized Ratio values. We determined whether dose adjustments were consistent with algorithm recommendations but could not verify whether providers used the algorithm. Using multilevel regression models to adjust for patient, center, and country characteristics, we assessed whether algorithm-consistent warfarin dosing could predict patient TTR and the composite outcome of stroke, systemic embolism, or major hemorrhage. We included 6022 nonvalvular atrial fibrillation patients from 912 centers in 44 countries. We found a strong association between the proportion of algorithm-consistent warfarin doses and mean country TTR (R(2)=0.65). The degree of algorithm-consistency accounted for 87% of the between-center and 55% of the between-country TTR variation. Each 10% increase in center algorithm-consistent dosing independently predicted a 6.12% increase in TTR (95% confidence interval, 5.65-6.59) and an 8% decrease in rate of the composite clinical outcome (hazard ratio, 0.92; 95% confidence interval, 0.85-1.00).
CONCLUSIONS: Adherence, intentional or not, to a simple warfarin dosing algorithm predicts improved TTR and accounts for considerable TTR variation between centers and countries. Systems facilitating algorithm-based warfarin dosing could optimize anticoagulation quality and improve clinical outcomes in atrial fibrillation on a global scale. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00262600.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23027801     DOI: 10.1161/CIRCULATIONAHA.112.101808

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  40 in total

1.  Assessment of warfarin algorithms for hospitalized adults: searching for a safe dosing strategy.

Authors:  Jessica L Cohen; Elena Thompson; Liron Sinvani; Andrzej Kozikowski; Guang Qiu; Renee Pekmezaris; Alex C Spyropoulos; Jason J Wang
Journal:  J Thromb Thrombolysis       Date:  2019-11       Impact factor: 2.300

2.  Quality of anticoagulation control and hemorrhage risk among African American and European American warfarin users.

Authors:  Nita A Limdi; Todd M Brown; Aditi Shendre; Nianjun Liu; Charles E Hill; Timothy M Beasley
Journal:  Pharmacogenet Genomics       Date:  2017-10       Impact factor: 2.089

Review 3.  2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures.

Authors:  Gyorgy Frendl; Alissa C Sodickson; Mina K Chung; Albert L Waldo; Bernard J Gersh; James E Tisdale; Hugh Calkins; Sary Aranki; Tsuyoshi Kaneko; Stephen Cassivi; Sidney C Smith; Dawood Darbar; Jon O Wee; Thomas K Waddell; David Amar; Dale Adler
Journal:  J Thorac Cardiovasc Surg       Date:  2014-06-30       Impact factor: 5.209

4.  Warfarin for prevention of thromboembolism in atrial fibrillation: comparison of patient characteristics and outcomes of the "Real-World" Michigan Anticoagulation Quality Improvement Initiative (MAQI2) registry to the RE-LY, ROCKET-AF, and ARISTOTLE trials.

Authors:  Andrew B Hughey; Xiaokui Gu; Brian Haymart; Eva Kline-Rogers; Steve Almany; Jay Kozlowski; Dennis Besley; Gregory D Krol; Syed Ahsan; Scott Kaatz; James B Froehlich; Geoffrey D Barnes
Journal:  J Thromb Thrombolysis       Date:  2018-10       Impact factor: 2.300

5.  Analysis of the first therapeutic-target-achieving time of warfarin therapy and associated factors in patients with pulmonary embolism.

Authors:  Xiaowei Gong; Haiyan Wang; Yadong Yuan
Journal:  Exp Ther Med       Date:  2016-08-23       Impact factor: 2.447

Review 6.  Vitamin K antagonists and time in the therapeutic range: implications, challenges, and strategies for improvement.

Authors:  Elaine M Hylek
Journal:  J Thromb Thrombolysis       Date:  2013-04       Impact factor: 2.300

Review 7.  Top practice-changing articles over the last two years.

Authors:  Scott Kaatz; Brian F Gage
Journal:  J Thromb Thrombolysis       Date:  2013-04       Impact factor: 2.300

8.  A prospective validation of the SAME-TT2R 2 score: how to identify atrial fibrillation patients who will have good anticoagulation control on warfarin.

Authors:  Daniela Poli; Emilia Antonucci; Sophie Testa; Gregory Yoke Hong Lip
Journal:  Intern Emerg Med       Date:  2014-03-21       Impact factor: 3.397

9.  Bleeding complications and liver injuries during phenprocoumon treatment: a multicentre prospective observational study in internal medicine departments.

Authors:  Sven Schmiedl; Marietta Rottenkolber; Jacek Szymanski; Werner Siegmund; Marion Hippius; Katrin Farker; Bernd Drewelow; Joerg Hasford; Petra Thürmann
Journal:  Dtsch Arztebl Int       Date:  2013-04-05       Impact factor: 5.594

10.  Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: Proceedings, Washington, DC, December 3-4, 2012.

Authors:  Paul L Hess; Michael J Mirro; Hans-Christoph Diener; John W Eikelboom; Sana M Al-Khatib; Elaine M Hylek; Hayden B Bosworth; Bernard J Gersh; Daniel E Singer; Greg Flaker; Jessica L Mega; Eric D Peterson; John S Rumsfeld; Benjamin A Steinberg; Ajay K Kakkar; Robert M Califf; Christopher B Granger
Journal:  Am Heart J       Date:  2014-04-24       Impact factor: 4.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.